Tower Research Capital (TRC)’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-43,752
| Closed | -$58K | – | 7085 |
|
|
2022
Q1 | $58K | Sell |
43,752
-2,018
| -4% | -$2.53K | ﹤0.01% | 2620 |
|
|
2021
Q4 | $62K | Buy |
45,770
+39,925
| +683% | +$94.4K | ﹤0.01% | 2604 |
|
|
2021
Q3 | $17K | Sell |
5,845
-116
| -2% | -$386 | ﹤0.01% | 3906 |
|
|
2021
Q2 | $21K | Buy |
5,961
+1,040
| +21% | +$3.57K | ﹤0.01% | 3866 |
|
|
2021
Q1 | $17K | Sell |
4,921
-3,157
| -39% | -$59.7K | ﹤0.01% | 4033 |
|
|
2020
Q4 | $155K | Sell |
8,078
-7,150
| -47% | -$110K | ﹤0.01% | 1952 |
|
|
2020
Q3 | $205K | Buy |
15,228
+13,370
| +720% | +$379K | ﹤0.01% | 2556 |
|
|
2020
Q2 | $79K | Buy |
1,858
+438
| +31% | +$14.2K | ﹤0.01% | 2668 |
|
|
2020
Q1 | $39K | Buy |
+1,420
| New | +$41.4K | ﹤0.01% | 1407 |
|
|
2019
Q3 | – | Sell |
-1,703
| Closed | -$63K | – | 4713 |
|
|
2019
Q2 | $63K | Buy |
1,703
+880
| +107% | +$21.1K | ﹤0.01% | 1461 |
|
|
2019
Q1 | $18K | Sell |
823
-4,334
| -84% | -$75.8K | ﹤0.01% | 2345 |
|
|
2018
Q4 | $72K | Sell |
5,157
-131
| -2% | -$2.04K | 0.01% | 1113 |
|
|
2018
Q3 | $102K | Buy |
5,288
+3,650
| +223% | +$74.4K | 0.01% | 1336 |
|
|
2018
Q2 | $36K | Sell |
1,638
-2,375
| -59% | -$55.3K | ﹤0.01% | 2063 |
|
|
2018
Q1 | $85K | Buy |
+4,013
| New | +$94.6K | 0.01% | 1376 |
|
Tower Research Capital (TRC)'s ODT Position: Q2 2022 in Review
Tower Research Capital (TRC) sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q2 2022, closing a stake of 43,752 shares — an estimated $58K sold.
Tower Research Capital (TRC) first reported a position in ODT in Q1 2018 and held it in 15 quarters. The position peaked at $205K in Q3 2020. 0 funds tracked by Wall St. Rank hold ODT as of Q2 2022.
- Tower Research Capital (TRC) reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
- Tower Research Capital (TRC) sold 43,752 Odonate Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $58K.
- Tower Research Capital (TRC) first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2018 and held it in 15 quarters.
- Tower Research Capital (TRC)'s Odonate Therapeutics, Inc. Common Stock position peaked at $205K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q2 2022.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2022, filed 15 Aug 2022.